Menopause is a single day — the 12-month anniversary of your final menstrual period. Everything before that, going back as much as a decade, is perimenopause: the transitional window when ovarian function becomes erratic before it eventually winds down. The international STRAW+10 staging system, the reference framework for clinicians and researchers, splits this window into 'early menopause transition' (persistent difference of ≥7 days between consecutive cycles) and 'late menopause transition' (skipped cycles, gaps of ≥60 days). Postmenopause begins one year after the last period and lasts for the rest of life.

For most women, perimenopause starts somewhere between 40 and 47, though a meaningful minority experience it earlier. The SWAN cohort — the longest longitudinal study of the transition in a multi-ethnic US sample — found a median total duration of frequent hot flashes of 7.4 years, with a median persistence of 4.5 years after the final period. So the popular image of menopause as a brief inconvenience is not what the data show. It is closer to a life chapter than a season.

Three framings to drop early: perimenopause is not a disease, not a deficiency, and not a one-symptom syndrome. It is a normal — if often demanding — endocrine transition, and the experience is wildly variable. Some women barely notice. Roughly a quarter report symptoms severe enough to interfere with work or relationships. Both are normal. Knowing where you are in the staging matters because the same symptom can mean different things at age 43 with regular periods than at 51 after a year of skipped ones.

Perimenopause is not a hot-flush problem with extras. It is a multi-system transition, and the symptom mix varies between women and across time within the same woman.

Vasomotor symptoms — hot flushes and night sweats — are the most recognised feature, affecting roughly 75–80% of women at some point. Severity ranges from background warmth to drenching night sweats that fragment sleep for years. Sleep disturbance is its own beast: SWAN and the Joffe et al. GnRH-agonist experimental work confirm a causal link between objective hot flashes and worsened objective sleep efficiency. But many women also develop insomnia patterns that are independent of night sweats — early waking, racing-mind insomnia, lighter sleep architecture. The two compound each other.

Mood and cognition deserve careful framing. Perimenopause genuinely elevates risk for new-onset depression and anxiety, even in women with no prior history. This is biology, not weakness, and it warrants real attention — not self-diagnosis. If mood symptoms feel disproportionate to your circumstances or persist for weeks, talking to your GP or a Hausärztin/Frauenärztin should not wait. On cognition: SWAN's longitudinal data (Greendale 2009) identified a measurable but reversible dip in processing speed and verbal memory during the perimenopausal transition that recovers in early postmenopause. So the 'brain fog' is real and is usually not the start of dementia.

Urogenital changes are widely under-discussed: vaginal dryness, recurrent UTIs, urinary urgency, and discomfort during sex are common, often arrive late in the transition, and unlike hot flushes do not resolve on their own. Joint aches ('the menopause joint'), heart palpitations, migraine pattern shifts, weight redistribution toward the midsection, and changes in skin and hair texture round out the picture. None of these are imagined. None of them are individually diagnostic.

The popular story is that estrogen 'drops' — but that is misleading for perimenopause. The defining feature of the early transition is volatility, not depletion. Estradiol can spike well above premenopausal levels in some cycles and then crash in others. FSH rises as the brain shouts louder at increasingly unresponsive ovaries, but FSH itself is erratic during early perimenopause, which is why a single blood test on a random cycle day is almost meaningless for diagnosis in your 40s. Diagnosis at this stage is clinical, based on cycle pattern changes and symptoms.

Cardiometabolic biology shifts in ways that compound aging effects. The SWAN heart study and others document an acceleration of visceral fat accumulation, a less favourable lipid profile (rising LDL, declining HDL), and a measurable bump in cardiovascular risk markers across the transition, partly independent of weight change. Bone density loss also accelerates: the highest annual rate of trabecular bone loss occurs in the year before and the two years after the final menstrual period, which is one reason early identification of risk matters.

The brain itself adapts. The Mosconi 2021 multi-modality neuroimaging study compared pre-, peri-, and postmenopausal women and reported stage-related differences in brain structure, connectivity, and energy metabolism, with grey-matter volume and some metabolic measures appearing more favourable in postmenopause than in perimenopause. The study is cross-sectional, so 'recovery' is inferred from between-group differences rather than tracked within individuals over time. This is a likely neurobiological correlate of brain fog. None of this means the brain is breaking. It means it is reorganising under different hormonal conditions.

Some interventions are well-supported by trials; others are wishful thinking with a wellness budget. Here is the honest map.

Strength training is the highest-leverage lifestyle intervention for this life stage, full stop. The LIFTMOR trial (Watson et al. 2018) showed that high-intensity progressive resistance and impact training improved bone mineral density at the spine and femoral neck in postmenopausal women with low bone mass — a population previously told to avoid heavy loading. Skeletal muscle also remains the largest glucose sink in the body, which directly counters the metabolic drift of the transition. Two to three structured sessions per week, with progressive loading, is the prescription.

Sleep hygiene becomes non-optional, but be realistic: when night sweats are the driver, behavioural sleep interventions alone are partial. Cooling the bedroom (16–18°C), moisture-wicking sleepwear, and a consistent wake time help. Cognitive behavioural therapy for insomnia (CBT-I) has the strongest evidence base for chronic insomnia in this population and is reimbursable through statutory health insurance (gesetzliche Krankenkasse) in Germany.

Dietary patterns: the evidence here is messier than wellness marketing would suggest. Mediterranean-style eating is associated with better cardiometabolic outcomes broadly, including in midlife women. Specific claims for 'menopause diets' or phytoestrogen-heavy protocols rest mostly on observational and short-term trial data — useful, not definitive. Adequate protein (roughly 1.2–1.6 g/kg body weight) supports muscle retention with strength training. Alcohol reliably worsens hot flashes and sleep for most women in this stage; reducing it tends to pay off quickly.

Stress regulation is genuinely physiological here, not just a wellness add-on. The HPA axis and sex steroid axes are entangled, and unmanaged chronic stress amplifies symptom severity. Anything with RCT evidence — mindfulness-based stress reduction, yoga, structured aerobic exercise — is reasonable. What does not have strong evidence: supplement stacks marketed for menopause, 'cortisol detoxes', and bioidentical compounded preparations sold outside clinical channels.

This is the topic where the discourse has done the most damage and is now slowly course-correcting. The headline: hormone therapy (HRT in the UK, MHT — menopausal hormone therapy — in current international usage) is back in the mainstream conversation for symptomatic women, but the decision is genuinely individual and belongs in a consultation with your Frauenärztin, Gynäkologin, or Wahlärztin (Austria), not on the internet.

The three references that matter in 2026: NICE NG23 (UK, updated November 2024), the NAMS 2022 Hormone Therapy Position Statement, and the DGGG/OEGGG S3 Leitlinie Peri- und Postmenopause (AWMF 015-062, version 2020 with September 2020 addendum; AWMF validity expired end of 2024, revision underway). All three converge on similar core principles, even if dosing and product details differ.

What current guidelines broadly agree on, in plain terms: for healthy women under 60 or within 10 years of menopause, with bothersome vasomotor symptoms, the benefit-risk profile of MHT is generally favourable. The headline harm signals from the original Women's Health Initiative (WHI) reports were partly an artefact of an older study population (mean age 63) and have been reframed by subsequent re-analyses. The 18-year follow-up by Manson et al. (JAMA 2017) found no significant difference in all-cause mortality between women randomised to hormone therapy versus placebo over long-term follow-up. The ELITE trial (Hodis et al. NEJM 2016) directly tested the 'timing hypothesis' and showed an effect on the progression of subclinical atherosclerosis only in women initiating therapy within six years of menopause, not later (ELITE's benefit was on a surrogate measure, not on clinical cardiovascular events).

Breast cancer risk is formulation- and duration-dependent. In WHI long-term follow-up (Chlebowski et al. JAMA 2020), the increase in breast cancer incidence was concentrated in the combined oestrogen + progestin arm (CEE + MPA). The oestrogen-alone arm (CEE in women after hysterectomy) showed no comparable increase and, on extended follow-up, a significant reduction in both breast cancer incidence and breast cancer mortality. A flat 'HRT raises breast cancer' summary therefore over-simplifies.

What this does not mean: it does not mean MHT is risk-free, it does not mean every woman should be on it, and it does not mean compounded 'bioidentical' preparations are safer than regulated products — they are not, and major guidelines specifically caution against unregulated compounded formulations. Individual breast cancer risk, cardiovascular history, migraine pattern, type of progestogen used, and route of administration all matter. The point is that a flat 'HRT is dangerous' position is not where the evidence sits in 2026, and the conversation deserves a real consultation rather than a default no.

There is no perimenopause panel that gets reimbursed by your Krankenkasse as a screening package. What is and isn't covered depends on what is investigated and why. A practical approach:

What the gesetzliche Krankenkasse generally covers when clinically indicated: gynaecological exam, basic blood work (TSH, ferritin, full blood count, lipids, HbA1c when risk factors present), and bone density measurement (DEXA/Knochendichtemessung) when there is a fracture history or clear osteoporosis risk. Note: DEXA as routine screening before age 65 in asymptomatic women is typically not covered and falls into IGeL/Selbstzahler territory.

Where private/IGeL pricing usually applies: 'menopause panels' with estradiol, FSH, LH, AMH, and progesterone; comprehensive cardiometabolic panels beyond standard lipids; and elective DEXA for baseline tracking. Hormone testing is also genuinely cycle-day-dependent — a randomly timed estradiol in early perimenopause can read anywhere — so insist that any hormone panel comes with a specific cycle-day rationale or it is essentially a vanity test. In Austria, the Wahlärztin pathway gives you longer appointments and easier access to extended panels, with partial reimbursement through the e-card system afterward.

Mental health screening matters and gets routinely under-included. A validated questionnaire (PHQ-9 for depression, GAD-7 for anxiety) takes five minutes and is the right baseline at this life stage. If it flags anything, GKV-covered psychotherapy referral exists in Germany, although waiting lists are long.

An honest minimum baseline for most women entering or in perimenopause: blood pressure, lipid panel, HbA1c, TSH, ferritin, vitamin D (if not measured in the last two years), and at least one validated mental-health questionnaire. DEXA is reasonable to consider as a baseline IGeL if there is family history of osteoporosis or any fragility-fracture history. Cycle tracking — through a notebook or app — is a high-value self-knowledge tool, but not a diagnostic.